Edit
Petros Pharmaceuticals (formerly Metuchen Pharmaceuticals)
http://petrospharma.com/Last activity: 13.07.2023
Active
Petros is committed to becoming the world’s leading men’s health company by identifying, developing, acquiring and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease (acute and chronic), hormone health and substance use disorders.
Petros’s current portfolio of men’s health products include the PDE-5 inhibitor drug Stendra® (avanafil) and the Timm Medical line of products. Stendra is an FDA- and EMEA-approved PDE-5 inhibitor drug used to treat erectile dysfunction. Stendra was initially launched in late 2013 and is patent protected through 2025. Timm Medical has a line of men’s health devices.
Petros trades on the Nasdaq Global Market under the ticker symbol “PTPI.”
Petros’s current portfolio of men’s health products include the PDE-5 inhibitor drug Stendra® (avanafil) and the Timm Medical line of products. Stendra is an FDA- and EMEA-approved PDE-5 inhibitor drug used to treat erectile dysfunction. Stendra was initially launched in late 2013 and is patent protected through 2025. Timm Medical has a line of men’s health devices.
Petros trades on the Nasdaq Global Market under the ticker symbol “PTPI.”
Location: United States, New York
Investors 1
| Date | Name | Website |
| - | Juggernaut... | juggernaut... |
Mentions in press and media 15
| Date | Title | Description |
| 13.07.2023 | Petros Pharmaceuticals Announces Capital Raise of $15 Million | - |
| 28.12.2021 | Petros Pharmaceuticals Announces Closing of $7.5 Million Offering | NEW YORK, Dec. 28, 2021 Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering and private placement with the comp... |
| 28.12.2021 | Petros Pharmaceuticals : Announces $7.5 Million Offering - Form 8-K | Petros Pharmaceuticals Announces $7.5 Million Offering December 22, 2021 Investors included the company's largest shareholder NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therape... |
| 22.12.2021 | Petros Pharmaceuticals Announces $7.5 Million Offering | NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that it has entered into definitive agreements with the company's largest investor and... |
| 22.12.2021 | Petros Pharmaceuticals Announces $7.5 Million Offering | NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that it has entered into definitive agreements with the company's largest investor and... |
| 02.12.2021 | Petros Pharmaceuticals : Announces $10 Million Offering - Form 8-K | Petros Pharmaceuticals Announces $10 Million Offering Investors included the company's largest shareholder NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's hea... |
| 02.12.2021 | Petros Pharmaceuticals Announces Closing of $10 Million Offering | NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering and private placemen... |
| 02.12.2021 | Petros Pharmaceuticals Announces Closing of $10 Million Offering | NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering and private placemen... |
| 30.11.2021 | Petros Pharmaceuticals Announces $10 Million Offering | NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements with the company's largest investor and... |
| 30.11.2021 | Petros Pharmaceuticals Announces $10 Million Offering | NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements with the company's largest investor and... |
Show more